Jonathan Moss to Humans
This is a "connection" page, showing publications Jonathan Moss has written about Humans.
Connection Strength
0.149
-
Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone. Anesthesiology. 2019 01; 130(1):142-148.
Score: 0.021
-
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016 11; 27(11):2032-2038.
Score: 0.018
-
Methylnaltrexone (Relistor®) does not impact opioid-mediated analgesia at therapeutic doses. Pain. 2014 Dec; 155(12):2722.
Score: 0.016
-
Effect of perioperative opioids on cancer recurrence: a hypothesis. Future Oncol. 2010 Aug; 6(8):1237-42.
Score: 0.012
-
Subcutaneous methylnaltrexone to restore postoperative bowel function in a long-term opiate user. Int J Gynecol Cancer. 2010 Feb; 20(2):308-10.
Score: 0.012
-
Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg. 2008 Dec; 107(6):1965-7.
Score: 0.011
-
Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc. 2008 Oct; 83(10):1116-30.
Score: 0.011
-
Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther. 2008 Jun; 7(6):1669-79.
Score: 0.010
-
Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005 May; 45(5):538-46.
Score: 0.008
-
Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med. 2004 Jul 06; 141(1):23-7.
Score: 0.008
-
The mu opioid receptor: A new target for cancer therapy? Cancer. 2015 Aug 15; 121(16):2681-8.
Score: 0.004
-
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577.
Score: 0.004
-
Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67.
Score: 0.003
-
The µ-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012 Apr; 116(4):940-5.
Score: 0.003
-
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011 Mar; 112(3):558-67.
Score: 0.003
-
Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007 Aug; 37(2):222-31.
Score: 0.002
-
Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med. 2007; 35(3):407-14.
Score: 0.002